Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glomerular mesangial cell proliferation is a pathological biological process characterized by the abnormal multiplication of mesangial cells within the kidney's glomeruli. It serves as a primary histological feature and driver of various progressive renal diseases, including IgA nephropathy, diabetic nephropathy, and lupus nephritis. This cellular expansion is typically triggered by injury-induced growth factors, most notably Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-beta (TGF-beta), which activate signaling cascades such as the Ras/MAPK and PI3K/Akt pathways. Uncontrolled proliferation leads to excessive production of extracellular matrix (ECM), resulting in mesangial expansion and eventually progressing to irreversible glomerulosclerosis and end-stage renal disease. Therapeutic intervention strategies focus on inhibiting the molecular drivers of this process rather than the proliferation itself as a single target. Common pharmacological approaches include the use of ACE inhibitors and ARBs to reduce hemodynamic triggers, immunosuppressants to control underlying inflammation, and experimental inhibitors targeting tyrosine kinases or cyclin-dependent kinases to arrest the cell cycle. Monitoring the progression or resolution of mesangial cell proliferation in clinical settings involves assessing biomarkers like proteinuria and renal function, as well as evaluating histopathological scores from renal biopsies. Understanding the regulation of this process remains critical for developing targeted therapies to preserve renal architecture and function.
Inhibition of mitogenic growth factor signaling (e.g., PDGF and TGF-beta pathways), induction of cell cycle arrest through cyclin-dependent kinase (CDK) inhibition, reduction of intraglomerular hemodynamic pressure, and suppression of inflammatory cytokine production.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glomerular mesangial cell proliferation (MCP).